hCG vs Semaglutide: Which Option May Be More Appropriate for Weight Management?

What Is Semaglutide?

Semaglutide is a medication that belongs to a class of drugs known as GLP-1 receptor agonists. These medications are designed to mimic a hormone naturally produced in the gut that helps regulate appetite, blood sugar, and digestion.

Clinical studies have shown that semaglutide may help reduce appetite and support weight reduction when combined with diet, physical activity, and ongoing medical supervision.

Mechanisms studied in clinical trials include:

• Enhancing insulin secretion in response to meals
• Reducing the release of glucagon
• Slowing the rate of stomach emptying
• Promoting a longer-lasting feeling of fullness

There are several FDA-approved formulations of semaglutide, including:

• Wegovy® – Approved by the FDA for chronic weight management in adults with obesity or overweight conditions and at least one weight-related health issue
• Ozempic® – Approved for improving blood sugar in adults with type 2 diabetes
• Rybelsus® – An oral version of semaglutide for the treatment of type 2 diabetes

Through Eden, patients may connect with licensed healthcare providers who may prescribe GLP-1 therapies when clinically appropriate. Medications are filled by state-licensed pharmacies.

Learn more about GLP-1 option via licensed healthcare providers via the Eden platform.
‍

What Is hCG?

Human Chorionic Gonadotropin (hCG) is a hormone naturally produced during pregnancy. In medicine, hCG is primarily used for fertility treatment and certain hormone-related conditions in both men and women, under the supervision of a licensed healthcare provider.

hCG has also been promoted in the past as part of extremely low-calorie diet programs aimed at weight loss. However, the U.S. Food and Drug Administration (FDA) has not approved hCG for weight loss, and these uses are not supported by modern clinical guidelines.

Research has shown that hCG does not contribute meaningfully to weight loss beyond what is achieved by calorie restriction alone. The combination of hCG and a very low-calorie diet (typically 500–800 calories per day) may carry significant health risks, including:

• Blood clots
• Hormonal imbalances
• Mood changes
• Fatigue and muscle loss

The FDA has issued warnings against the use of hCG for weight loss, citing both safety concerns and a lack of scientific evidence for effectiveness.

Note: Eden does not offer hCG-based treatments. Eden connects individuals with licensed healthcare providers to explore evidence-based options for metabolic health and weight management, including GLP-1 therapies when appropriate.
‍

Mechanism of Action Comparison

Understanding how different medications work can help patients have informed discussions with their healthcare providers. Below is a comparison of semaglutide and hCG based on their mechanisms of action and primary medical purposes:

‍

‍

Important: While semaglutide has been studied in the context of weight management, hCG has not been shown to be effective for weight loss beyond calorie restriction, and its use for this purpose has been discouraged by the FDA.

Pros and Cons

Semaglutide

Pros:

• Clinically studied for weight management: In trials like the STEP 1 study (NEJM, 2021), semaglutide was shown to support meaningful weight reduction when paired with lifestyle changes and medical oversight.
• Convenient dosing: Typically administered once weekly.
• May support improved metabolic markers: Such as fasting glucose and insulin sensitivity in individuals with type 2 diabetes.

Cons:

• Gastrointestinal side effects: Common side effects include nausea, constipation, and acid reflux, particularly during dose escalation.
• Access and cost: May be expensive without insurance or affordability programs.
• Ongoing use may be necessary: Discontinuing treatment without lifestyle support or clinical guidance may result in weight regain.

hCG

Pros:

• Approved for certain medical uses: Such as fertility support and testosterone-related therapy, under the care of a licensed provider.

Cons:

• Not FDA-approved for weight loss: The FDA has issued warnings regarding hCG used in diet programs.
• Limited to no clinical support for weight loss efficacy: Research does not show additional benefit when combined with calorie restriction.
• Potential safety concerns: Reported risks include blood clots, mood disturbances, hormonal imbalance, and muscle loss, especially when used in unsupervised programs.
• Not recommended for long-term weight management: Lacks support in clinical guidelines for sustained weight reduction.

Eden does not offer or promote hCG-based diet programs. Patients can use Eden’s platform to connect with licensed providers to explore safer, clinically supported options for metabolic health.

‍

Effectiveness Comparison

Effectiveness varies between treatment options and should always be evaluated under the guidance of a licensed healthcare provider. Below is a summary of published findings on semaglutide and hCG as they relate to weight management.

Semaglutide

Semaglutide has been studied extensively in randomized controlled trials for chronic weight management.

• In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), adults with obesity or overweight who used semaglutide 2.4 mg weekly, along with lifestyle changes, experienced an average weight loss of approximately 15% of body weight over 68 weeks.
• Participants also showed improvements in cardiometabolic markers such as waist circumference, blood pressure, and fasting glucose levels.

These results apply to the Wegovy® formulation of semaglutide, which is FDA-approved for chronic weight management in adults with a qualifying BMI and weight-related condition.

hCG

Despite being used in some weight loss programs, hCG has not demonstrated meaningful effectiveness for weight reduction when studied in controlled environments.

• Multiple clinical studies have shown no significant difference in weight loss between individuals using hCG and those receiving placebo, when both groups followed the same calorie-restricted diet.
• Institutions like the Mayo Clinic and the FDA have stated that hCG does not aid in fat loss and may pose health risks when used for this purpose.

hCG remains unapproved by the FDA for weight loss, and its use in this context is not supported by current medical guidelines. Mayo Clinic Position

Safety Profiles

‍

‍

Any medication should only be used under the guidance of a licensed healthcare provider. Eden does not prescribe or dispense medication, but helps patients connect with providers who can evaluate whether treatment is appropriate.

Cost Overview

The cost of treatment can vary significantly depending on the formulation prescribed, insurance coverage, and pharmacy pricing. Below is a general overview of out-of-pocket costs for each option. Please note that pricing may change based on your insurance coverage and may change post-publishing - please contact your insurance provider or the manufacturer for updated costs.

‍

‍

Through Eden, patients can connect with licensed healthcare providers who may prescribe GLP-1 medications when medically appropriate. If prescribed, medications are filled by state-licensed pharmacies.

Tip for patients: Insurance coverage may vary based on medical history and licensed healthcare provider documentation. Licensed healthcare providers accessed via the Eden platform may help explore cost-saving options when available.

Explore GLP-1 options with a licensed healthcare provider via the Eden platform.

Clinical Overview

When comparing semaglutide and hCG for weight-related goals, it’s important to consider the level of clinical support, regulatory status, and risk profile. The table below summarizes how each option aligns with medical guidelines and available evidence.

‍

‍

Eden helps patients connect with licensed healthcare providers who can evaluate whether GLP-1 therapy, such as semaglutide, is an appropriate option based on individual health needs.

Start your GLP-1 consultation with a licensed healthcare provider via the Eden platform.

‍